1.
Adenovirus-mediated gene therapy with sitimagene ceradenovec followed by intravenous ganciclovir for patients with operable high-grade glioma (ASPECT): a randomised, open-label, ph...
by Westphal, Manfred, Prof
The lancet oncology, 2013, Vol.14 (9), p.823-833
2.
Evolutionary patterns of hepatitis B virus quasispecies under different selective pressures: correlation with antiviral efficacy
by Liu, Feng
Gut, 2011-09, Vol.60 (9), p.1269-1277
3.
Simeprevir plus sofosbuvir, with or without ribavirin, to treat chronic infection with hepatitis C virus genotype 1 in non-responders to pegylated interferon and ribavirin and trea...
by Lawitz, Eric, Prof
The Lancet (British edition), 2014, Vol.384 (9956), p.1756-1765
4.
Efficacy and safety of glecaprevir/pibrentasvir in Japanese patients with chronic genotype 1 hepatitis C virus infection with and without cirrhosis
by Chayama, Kazuaki
Journal of gastroenterology, 2017-09-25, Vol.53 (4), p.557-565
5.
Ribavirin and interferon alfa-2a for severe Middle East respiratory syndrome coronavirus infection: a retrospective cohort study
by Omrani, Ali S, FRCP
The Lancet infectious diseases, 2014, Vol.14 (11), p.1090-1095
6.
Treatment with interferon-α2b and ribavirin improves outcome in MERS-CoV-infected rhesus macaques
by Falzarano, Darryl
Nature medicine, 2013-10, Vol.19 (10), p.1313-1317
7.
Glecaprevir plus pibrentasvir for chronic hepatitis C virus genotype 1, 2, 4, 5, or 6 infection in adults with compensated cirrhosis (EXPEDITION-1): a single-arm, open-label, multi...
by Forns, Xavier
The Lancet infectious diseases, 2017-10, Vol.17 (10), p.1062-1068
8.
Antiviral Drugs for Viruses Other Than Human Immunodeficiency Virus
by Razonable, Raymund R., MD
Mayo Clinic proceedings, 2011, Vol.86 (10), p.1009-1026
9.
Analysis of the susceptibility to COVID-19 in pregnancy and recommendations on potential drug screening
by Zhao, Xiaoxuan
European journal of clinical microbiology & infectious diseases, 2020-04-23, Vol.39 (7), p.1209-1220
10.
Efficacy of boceprevir, an NS3 protease inhibitor, in combination with peginterferon alfa-2b and ribavirin in treatment-naive patients with genotype 1 hepatitis C infection (SPRINT...
by Kwo, Paul Y, Dr
The Lancet (British edition), 2010, Vol.376 (9742), p.705-716
11.
All-oral daclatasvir plus asunaprevir for hepatitis C virus genotype 1b: a multinational, phase 3, multicohort study
by Manns, Michael, Prof
The Lancet (British edition), 2014, Vol.384 (9954), p.1597-1605
12.
Virological response after 6 week triple-drug regimens for hepatitis C: a proof-of-concept phase 2A cohort study
by Kohli, Anita, MD
The Lancet (British edition), 2015, Vol.385 (9973), p.1107-1113
13.
Sofosbuvir in combination with peginterferon alfa-2a and ribavirin for non-cirrhotic, treatment-naive patients with genotypes 1, 2, and 3 hepatitis C infection: a randomised, doubl...
by Lawitz, Eric, Prof
The Lancet infectious diseases, 2013, Vol.13 (5), p.401-408
14.
Unraveling the divergent results of pre-exposure prophylaxis trials for HIV prevention
by VAN DER STRATEN, Ariane
AIDS (London), 2012, Vol.26 (7), p.F13-F19
15.
Systematic review: patient‐reported outcomes in chronic hepatitis C ‐ the impact of liver disease and new treatment regimens
by Younossi, Z.
Alimentary pharmacology & therapeutics, 2015-03, Vol.41 (6), p.497-520
16.
Antibody responses to SARS-CoV-2 in patients with COVID-19
by Long, Quan-Xin
Nature medicine, 2020-06, Vol.26 (6), p.845-848
17.
Retrospective comparison of convalescent plasma with continuing high-dose methylprednisolone treatment in SARS patients
by Soo, Y.O.Y
Clinical microbiology and infection, 2004-07, Vol.10 (7), p.676-678
18.
Association between adverse clinical outcome in human disease caused by novel influenza A H7N9 virus and sustained viral shedding and emergence of antiviral resistance
by Hu, Yunwen, MD
The Lancet (British edition), 2013, Vol.381 (9885), p.2273-2279
19.
Hepatitis B virus infection
by Liaw, Yun-Fan, Prof
The Lancet (British edition), 2009, Vol.373 (9663), p.582-592
20.
Association between antiviral treatment and extrahepatic outcomes in patients with hepatitis C virus infection
by Hsu, Yao-Chun
Gut, 2015-03, Vol.64 (3), p.495-503
